Clinical trial

Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

Recruiting now · Phase 3 · 1 countries · Registry ID NCT04578652

Recruiting nowPhase 3Interventional

What this study is about

This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function. Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM. .

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age12 Years to 18 Years

SexAll

Healthy volunteersNot accepted

ConditionObesity, Childhood, Insulin Resistance

Full registry criteria

Inclusion Criteria: 1. Age 12-18 years 2. BMI percentile \> 95% for age/sex; 3. Total weight fluctuation over past 6 months \< 10%; 4. HOMA-IR \> 3.16; 5. FH of T2DM (first or second-degree relative). Exclusion Criteria: 1. Current use of insulin or diagnosis of T2DM; 2. Systolic or diastolic blood pressure (BP) \> 99th percentile for age and sex; 3. Acute infectious or inflammatory condition over the preceding 1 month; hospitalization \> 48 hrs; 4. History of chronic disease such as inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders; 5. Active malignancy; 6. Concomitant use of medication/investigational drug known to affect body weight in the past year; 7. Antibiotic use in past 60 days; probiotic and/or prebiotic supplements use in the past 30 days; use of lipid-lowering and anti-inflammatory medication.

Treatments and study arms

Metformin 850 mg oral tablet bid

Drug

MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).

Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.

Dietary Supplement

The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.

Primary outcomes

Changes in HOMA-IRBaseline, 6, and 12 months

Change in HOMA-IR value

Study locations

1 locations were listed when this page was built. The first 40 are shown.

University of Alberta🇨🇦 Edmonton, Alberta, Canada

Open map

Andrea M Haqq, MD, MHSContact

Email · Call 780-492-0015

Andrea M Haqq, MD, MHSPrincipal Investigator